Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The company will manufacture a cancer immunotherapy product from 2022
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
Subscribe To Our Newsletter & Stay Updated